Tag Archives: BIO Investor Forum

BIO Investor Forum Company Snapshot: Vaccinex

Vaccinex

Recently, the CEO of Prosensa provided their company’s perspective participating in last year’s BIO Investor Forum. Looking ahead at this year’s event, we spoke to the President & CEO of Vaccinex, Dr. Maurice Zauderer. They will be presenting in the regular private track, which features later-stage private companies. Read below to learn more about this biotech.   Company Snapshot What is your company’s lead product or technology? Vaccinex’s lead product, VX15, is an antibody to semaphorin Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

12th Annual BIO Investor Forum Presenting Companies Announced

San Francisco skyline

Looking to lose a few pounds? Don’t want to diet or exercise? You’re not alone: fully one-third of Americans are obese, and many companies are trying to discover the first blockbuster diet drug and make a dent in the obesity epidemic. We’ll hear from one of those companies next month at the 12th Annual BIO Investor Forum, taking place October 8-9th in San Francisco. Cambridge-based Zafgen is hoping to bring to market their first-in-class obesity Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Prosensa’s IPO and the Value of the BIO Investor Forum

Hans Schikan

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Our primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease. We completed an IPO onto NASDAQ in June of this year. Prior to last year’s BIO Investor Forum in San Francisco, we were still in the very Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

JOBS Act Provides Innovators with Capital Boost

jobs-act-article

Despite all the talk of gridlock and polarization in Washington these days, successful, bipartisan pieces of legislation are not a thing of the past. One of them is the Jumpstart Our Business Startups (JOBS) Act, which makes it easier for emerging growth companies to raise capital by going public. The JOBS Act provides qualifying companies with a five year “on-ramp” period to comply with some of the regulatory requirements involved when making the transition from Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Investor Forum Company Snapshot: NovelMed Therapeutics

NovelMed

NovelMed Therapeutics will be presenting at the upcoming BIO Investor Forum in October in San Francisco. Read below to learn more about their antibodies portfolio, what differentiates their company for the competition, and other interesting facts about the company. Company Snapshot What is your company’s lead product or technology? NovelMed has developed a portfolio of fully humanized monoclonal antibodies that selectively target only the disease-associated Complement System. As such, NovelMed’s antibodies are active against multiple Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,